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ABSTRACT 
In this report, we present data showing that a recombinant adenoviral vector (Ad.RSV/L-ira) containing the 
c D N A for h u m a n interleukin-1 receptor antagonist protein (IL-lra) can genetically modify synoviocytes both 
in vitro and in vivo. H u m a n synoviocytes infected with Ad.RSV/L-7ra in vitro expressed and secreted high levels 
ofhuman IL-lra that were detected by E L I S A of tissue culture supernatants. N e w Zealand White rabbits that 
received intra-articular injections of Ad.RSV/L-7ra expressed transgenic IL-lra in synoviocytes, and secretion 
was detected for at least 4 weeks post-infection. Further, biological activity of the transgenic IL-lra was 
demonstrated by its ability to inhibit IL-1-induced prostaglandin Ej (PGEj) synthesis in vitro and IL-1-induced 
glycosaminoglycan ( G A G ) degradation in vivo. These data demonstrate that recombinant adenoviral vectors 
can mediate the intra-articular expression of anti-inflammatory proteins and m a y be a reasonable method to 
deliver therapeutically relevant proteins for the regional treatment of synovial inflammation. 
OVERVIEW SUMMARY INTRODUCTION 
Adenovirus-mediated gene transfer into the cells of the syn-
ovial membrane may provide a means to deliver therapeuti-
cally active proteins for the local modification of the im-
mune response in inflammatory arthropathies. In this 
study, we infected type B human synoviocytes in vitro and 
rabbit synovial lining membrane in vivo with a recombinant 
human adenovirus containing the cDNA for the human in-
terIeukin-1 receptor antagonist protein (IL-lra). Expres-
sion of human IL-lra was observed both in the transduced 
synoviocytes in vitro and in the microenvironment of the 
transduced rabbit synovial membrane in vivo, and the func-
tional activity of the transgenic IL-lra was suggested by in 
vitro inhibition of interleukin-1 (IL-l)-induced prostaglan-
din E2 (PGEj) production and by in vivo inhibition of IL-1-
induced glycosaminoglycan (GAG) degradation. 
DIARTHRODIAL JOINTS ARE LINED BY SYNOVIAL MEMBRANE, 
a complex multifunctional mesothelial layer of one to four 
cells supported by loose vascular connective tissue. Ultrastruc-
tural studies of the synovial membrane have indicated that at 
least two major tyfws of cells are present within the synovial 
membrane (Barland etal., 1962). Type A cells have phagocytic 
capability and endocytic vacuoles, and are thought to be de-
rived from the monocyte lineage. Type B cells, in contrast, 
have secretory features such as an active Golgi, abundant endo-
plasmic reticulum, and intracytoplasmic granules. These cells 
are believed to be specialized mesenchymal cells of fibroblast 
origin. In addition, cells with an intermediate ultrastructural 
appearance and morphology may exist within adult synovium 
(Roy era/., 1966). 
In inflamed joints, the synovial lining increases to five to ten 
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cell layers, primarily by the accumulation of type A synovio-
cytes (Broker et al.. 1990). At the same time, the formerly 
quiescent type B cells change into aggressive, proliferating, 
invasive cells that display many features of a "transformed" 
phenotype, such as oncogene expression and metalloprotease 
excretion (Lafyatis et al., 1989; Gay et al., 1993). Previous 
work has shown that these changes in the synovial membrane 
are mediated by a variety of effector molecules associated with 
rheumatoid arthritis, and synoviocytes themselves have been 
shown to secrete several of these cytokines (Harris, 1990). 
One of these cytokines, interleukin-1 (IL-1), functions as a 
central mediator of inflammation. Multiple studies have eluci-
dated the importance of regional IL-1 production in the genera-
tion and maintenance of synovial inflammation (Wood et al., 
1985; Miossec et al., 1986; Mochan et al., 1986; Kumkumian 
et al., 1989). IL-1 stimulates lL-2 production and induces the 
expression of IL-2 receptors on T cells (Smith et al., 1980). 
These effects permit antigen-stimulated T cells to expand in 
number. IL-1 is also critical for B-cell proliferation and immu-
noglobulin production (Falkoff ef a/., 1984). In addition, IL-1 
stimulates type B synoviocytes to secrete metalloproteases, 
such as stromelysin (Mizel et al.. 1981; Dayer et al., 1984; 
1986; McCroskery era/., 1985; Stashenko era/., 1987; Case ef 
al., 1989). IL-1 also induces prostaglandin Ej (PGEj) produc-
tion (Mizel et al., 1981; Dayer ef al., 1986) and glycosamino-
glycan (GAG) degradation (Yaron etal., 1987). 
A n endogenous interleukin-1 receptor antagonist protein (IL-
lra) has previously been isolated and cloned. This natural an-
tagonist protein is structurally related to IL-la and IL-1 (3 and 
competes with these cytokines for occupancy of IL-1 cell-sur-
face receptors. Since IL-lra does not trigger signal transduc-
tion, it functions as a competitive inhibitor. Previous studies 
have demonstrated that many IL-1 effects can be blocked by 
native IL-lra, such as the induction of PGEt synthesis by syn-
ovial cells and fibroblasts (Seckinger ef a/., 1987; Arend etal., 
1989), the inhibition of G A G production in human articular 
cartilage cultures (Seckinger et al., 1990), the stimulation of 
hyaluronic acid production by human synoviocytes (Seckinger 
etal.. 1990), and the production of collagenase by rabbit artic-
ular chondrocytes (Arend ef al., 1989). 
The recent characterization of IL-lra suggests that this pro-
tein plays a crucial role in regulating IL-1 activity, and has 
raised the possibility of using this molecule as a therapeutic 
agent. Regional overexpression of this molecule would be ex-
pected to reduce tissue inflammation by inhibiting lL-1 activity 
(Stashenko ef a/., 1987; Arend ef a/., 1990; Carter ef a/., 1990; 
Eisenberg et al., 1990; Dinarello, 1992). Gene therapy pro-
vides a testable method for augmenting the local production of 
IL-lra. Previous studies have shown the feasibility of this ap-
proach by demonstrating that synovial tissues can be modified 
to secrete IL-la following ex vivo retroviral transduction (Ban-
dara ef al., 1993). Further, the ultrastructural organization of 
the synovial membrane suggests that synovitis may be espe-
cially suited to gene therapy. The synovial lining cells lack a 
cleariy defined basement membrane, and endothelial cells (up 
to 1 0 % ofthe total cell population) are directly subjacent to this 
membrane. The lack of any anatomic barrier between the lining 
cells and the endothelium suggests that overexpression of solu-
ble cytokine inhibitors by synovial cells may cause clinically 
relevant effects within the local microenvironment with regard 
to inflammatory cell recruitment, retention, and activation. If 
sufficient levels of cytokine inhibitor expression were present, 
an anti-inflammatory effect might be observed within the intra-
articular space of a specific joint. 
In the current report, we describe the construction of an 
adenoviral vector containing the c D N A for human IL-lra 
(Ad.RSV/L-7ra) and provide data showing that both human 
synovium transduced by Ad.RSV/Z,-7ra in vitro and rabbit syn-
ovial tissue transduced by Ad.RSV/L-//-a in vivo secrete bio-
logically active IL-lra. 
MATERIALS AND METHODS 
Generation of Ad.RSVlh-lxdi 
Ad.RSV/L-ira is a replication-defective adenoviral vector 
based on an AdS serotype viral genomic backbone. This virus is 
deleted of sequences spanning E I A and EIB (1-9 map units), 
resulting in an impaired ability to replicate or to transform 
nonpermissive cells (Logan ef al., 1984; Davidson ef al., 
1993). The EIB deletion interrupts the E1B-19K coding region. 
In addition, the recombinants are deleted in the E3 region 
(83-85 map units). This deletion interrupts the open reading 
frames (ORFs) for the E3 region immunomodulatory genes 
gpl9K, 14.7K, and 10.4/14.5K. The Rous sarcoma virus 
(RSV) L T R drives the transgene transcription in this recombi-
nant vector. To construct this vector, the R S V promoter and the 
c D N A for human IL-lra (a gift from Immunex, Seattle, W A ) 
were cloned into the parent plasmid pAd.Bglll to generate the 
plasmid pAd.RSV/Z.-7/-a. [This proviral plasmid provides the 
5' inverted terminal repeat (ITR) sequence necessary for viral 
replication and encapsidation.] pAd.RSV/Z.-7ra was linearized 
by Nhe I digestion and cotransfected into permissive 293 cells 
with viral genomic D N A (AdS derivative sub360), which had 
been previously digested with Xba I and Cla I to achieve the 
E1-region deletion (Graham and Van Der Eb, 1973). Asaresult 
of homologous recombination (within 9.2-16.1 map units), an 
ElA/ElB-deleted recombinant adenovirus (Ad.RSV/Z,-7ra) 
containing the human IL-lra c D N A was produced. 
Candidate plaques were expanded and the identity of recom-
binant clones was verified by restriction analysis of viral D N A 
minipreps. High-titer viral suspensions for in vitro and in vivo 
studies were produced by amplification of triple plaque-purified 
stocks in 293 cells using a modification of established methods 
(Graham and Van Der Eb, 1973). Control viruses for in vitro 
and in vivo experiments were Ad.Bglll (an identical AdS-de-
rived adenoviral vector that does not contain a functional trans-
gene) and Ad.RSV/acZ (an AdS vector containing the gene for 
E. coli P-galactosidase). (Analyses of viral stocks for human 
IL-lra were below the detection limits of the commercial 
ELISA [<46 pg/ml].) 
In vitro infection of human synoviocytes 
Human type-B synoviocytes obtained from surgical speci-
mens at the time of elective prosthetic joint replacement were 
kindly provided by Dr. C W . Castor. Explanted synoviocytes 
were characterized phenotypically by the use of a ['"Cjglu-
cosamine to ['''CJhyaluronic acid incorporation assay (Castor, 
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1971). Synoviocytes were maintained in subconfluent mono-
layer cultures in air in T-7S flasks in C M R L 1066 medium 
(GIBCO BRL, Grand Island, NY) supplemented with S% hu-
man serum, 5 % fetal calf serum (FCS), 10% neonatal calf 
serum, 0.025% sodium bicarbonate, 2 m M L-glutamine, 0.02 
M H E P E S buffer, penicillin (IOO U/ml), streptomycin (IOO 
IJLg/ml), and gentamicin (5 p-g/ml). Synoviocytes were infected 
with purified suspensions of Ad.RSV7L-/ra at multiplicities of 
infection (moi) ranging from lO'-lO'* plaque forming units 
(pfu) per cell for a period of 4 hr, then grown out and main-
tained as confluent monolayer cultures for 7 days post-infec-
tion. At 1,4, and 7 days post-infection, cells were washed 
twice in PBS and then covered with fresh, serum-free C M R L 
1066 for 2 hr. Tissue culture supematants were removed, cen-
trifuged to remove cell debris, and frozen at —70°C. N o signif-
icant cytopathic effect was observed in the infected cells, which 
continued to grow at rates comparable to uninfected controls 
and to exhibit contact inhibition at confluence. The amount of 
human IL-lra present in the tissue culture supematants was 
determined using an ELISA specific for human IL-lra ( R & D 
Systems, Minneapolis, M N ) according to the manufacturer's 
instructions. 
PGE2 assays 
Third-passage rheumatoid synoviocytes were exposed to 
Ad.RSV/acZ or Ad.RSV7L-/ra, at a titer of 10* plaque forai-
ing units per synoviocyte for a period of 2 hr in C M R L 1066 
supplemented with 2 % FCS. The cells were then grown out in 
complete C M R L 1066 medium. Three days post-infection, 
multiple samples of synoviocytes (n = 10) were treated with 
medium supplemented with 1 % B S A and recombinant human 
IL-ip (rhIL-l(3, 3 U/ml; Genzyme, Cambridge, M A ) . After 12 
hr, the production of P G E ; by the synoviocytes in response to 
stimulation with rhIL-ip was determined by ELISA (PerSep-
tive Diagnostics, Cambridge M A ) of tissue culture supema-
tants. Results were expressed as picograms of P G E , per millili-
ter of supematant. 
In vivo studies 
Animal experiments were performed in accordance with in-
stitutional guidelines and approved by the University Commit-
tee on Use and Care of Animals. N e w Zealand White ( N Z W ) 
rabbits 2 kg in weight were used for these experiments, and 
freshly prepared suspensions of Ad.RSWIL-lra were used for 
intra-articular injections. Prior to the procedure, rabbits were 
anesthetized with a single intramuscular dose of ketamine/ 
xylazine. The area surrounding both hind knees was shaved and 
coated with providone/iodine. Using sterile technique and a 
medial approach, 1 ml of Ad.RSV7L-7ra suspension in phos-
phate-buffered saline (PBS) was injected into the intra-articular 
space of the right knee over a period of 30 sec. The left knee 
was prepared in an identical manner and injected with 1 ml of 
PBS or 1 ml of a control viras (Ad.Bglll or Ad.RSV/acZ). At 
time points from 4 days to 4 weeks post-infection, animals were 
euthanized with an intravenous overdose of pentobarbital. Skin 
and fascia were dissected away from the region of the knee and 
the joint space was exposed through an incision made along the 
medial border of the patellofemoral ligament. The joint space 
was lavaged with 2 ml of PBS over a period of approximately 2 
min, and the lavage fluid was recovered by aspiration. The fluid 
was centrifuged for 5 min at 10,000 x g to remove cellular 
debris and aliquots were frozen at -70°C until use. Representa-
tive samples of synovial tissue were dissected away from sur-
rounding stractures and were frozen in O C T . 
RESULTS 
The ability of the viras Ad.RSWIL-lra to transduce human 
synoviocytes and to mediate the expression of human IL-lra 
was determined using human synoviocytes in vitro. Human 
type B synoviocytes were infected with purified suspensions of 
Ad.RSV/i--7ra at various moi from 10^-10" pfu/cell for a pe-
riod of 4 hr, rinsed, and then maintained as confluent mono-
layer cultures for 7 days post-infection. The rate of transgenic 
IL-lra production by the infected synoviocytes in vitro was 
determined at 1,4, and 7 days post infection using an ELISA 
specific for human IL-lra ( R & D Systems). Ad.RSYIL-lra was 
able to mediate expression and secretion of human IL-lra by 
infected synoviocytes, with the concentration of IL-lra ranging 
from 10 to 100 p-g/hr • m g of total protein in supematants (Ta-
ble 1). 
Southem analysis was used to determine the transgenic IL-
lra copy number using total cellular D N A obtained from dupli-
TaBLE 1. In Vitro EXPRESSION AND SECRETION OF H U M A N 
IL-iRA Protein by H u m a n Synoviocytes Infected 
WITH AD.RSV7L-7ra 

































Human synoviocytes were maintained in monolayer cultures in air in 
T-75 flasks in C M R L 1066 medium (GIBCO) supplemented with 5% 
human serum, 5% FCS, 10% neonatal calf serum, 0.025% sodium 
bicarbonate, 2 m M L-glutamine, 0.02 M HEPES, penicillin (100 U/ml), 
streptomycin (100 fig/ml), and gentamicin (5 jig/ml). Synoviocytes 
were then infected in serum free medium at moi from 10^ to 10* viral 
particles per target cell with Ad.RSV7Z.-/ra, and 10* viral particles per 
cell for Ad.RSV/acZ (control) for 4 hr, washed extensively, and main-
tained as confluent cultures for 7 days. At 1, 4, and 7 days post-
infection, the synoviocytes were washed twice in PBS and then exposed 
to serum-free tissue culture medium for a period of 2 hr. Tissue culture 
supematants were collected and frozen at —70°C until use. Supema-
tants were then analyzed using an ELISA specific for human IL-lra 
(R&D Systems). Total protein concentration in the supematants was 
determined using the method of Lowry. 
"IL-lra production is expressed as (ig/hr • mg oftotal protein present 
in 10 ml of serum-free tissue culture supematant collected over a period 
of2hr. 
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cate aliquots of the infected cells harvested 48 hr post-infection. 
IL-Ira-specific sequences were detected as D N A fragments 
consistent with the known size of the parent adenoviral ge-
nome, the endogenous IL-lra gene, and the transgenic human 
IL-lra c D N A (Fig. 1, arrows). Although the occurrence of rare 
integrative events could not be excluded, no additional bands 
were observed when blots were overexposed (data not shown). 
Analysis of the blots using a phosphoimager (Molecular Dy-
namics, Sunnyvale, C A ) indicated that the number of viral 
genomes per target cell correlated with increasing doses of viras 
up to a moi of 10* pfu/cell, the highest dose tested. 
A n in vitro assay using Ad.RSV7i.-7ra transduced synovio-
cytes was done to determine if the transgenic IL-lra produced 
was biologically active. This assay was designed to test the 
ability of IL-1 ra to inhibit the production of P G E , in response to 
stimulation with exogenous recombinant human IL-ip (Fig. 2). 
Synoviocytes infected with Ad.RSV7i,-7ra produced signifi-
cantiy less PGE2 over 12 hr of incubation with rhIL-ip than 
cells infected with Ad.RSV/acZ (p < 0.001) or uninfected con-
trols (p < 0.001). N o significant difference was observed in 
PGEt production between mock-infected synoviocytes and 
synoviocytes infected with Ad.RSV/acZ (p = 0.067). 
Normal rabbit synovium was used as a target tissue to test the 
ability of Ad.RSV7L-7ra to mediate transgenic expression of 
biologically active IL-lra in vivo. Rabbits received intra-articu-
lar injections of purified Ad.RSV7Z.-7ra suspension 
(2.0 X 10'° pfu/mL) in PBS (total volume 1 ml) in the right 
knees. The left knee was prepared in an identical manner and 
injected with 1 ml of PBS or 1 ml ofthe control viras (Ad.Bglll 
or Ad.RSV/acZ). None of the rabbits experienced evidence of 
clinically relevant arthritis as determined by their ability to 
ambulate in their cages, lack of change in serially measured 
articular circumference, and absence of erythema overlying the 
periarticular skin. At 1-4 weeks post-infection, animals were 
euthanized with an intravenous overdose of pentobarbital and 
the synovial tissue examined for the expression of transgenic 
human IL-lra using in situ R N A hybridization. 
Sections of rabbit synovium transduced with Ad.RSV7L-7ra 
1 week previously hybridized strongly to probes antisense to 
human IL-lra sequences (Fig. 3B). Importantiy, samples of 
synovium infected with Ad.RSV/acZ (Fig. 3A) showed no in-
crease over background levels of antisense or sense probe hy-
bridization (Fig. 3C), indicating that the signal seen in B is due 
to transgenic IL-lra and not to up-regulated expression of en-
dogenous rabbit IL-lra. Similar negative results were seen 
when antisense probe was hybridized to sections of synovium 
from rabbit knees injected with PBS or Ad.Bglll (data not 
shown). Although the signal at 1 week was uniformly strong, 
synovial tissue sections from animals sacrificed 2 and 4 weeks 
post-infection had only scattered positive synoviocytes (data 
not shown). 
The ability of synovial cells to secrete IL-lra in vivo was 
determined by ELISA of lavage fluid. The normal rabbit knee 
contains little joint fluid, and importantly the rabbits did not 
develop joint effusions as a result ofthe intra-articular infection 
procedure. Therefore, the amount of transgenic IL-lra present 
within the knee joint at the time of sacrifice was determined 
indirectly by performing a post-mortem medial arthrotomy fol-
lowed by articular lavage with 2 ml of PBS. Fluid was collected 
by aspiration of the joint space, cellular debris removed by 
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FIG. 1. Southem analysis of human synoviocytes infected in 
vitro with Ad.RSV7L-7ra. H u m a n synoviocytes were main-
tained in monolayer cultures in air in T-75 flasks in C M R L 
1066 medium (GIBCO) supplemented with 5 % human seram, 
5 % fetal bovine seram, 1 0 % neonatal calf seram, 0.025% so-
dium bicarbonate, 2 m M L-glutamine, 0.02 M H E P E S buffer, 
penicillin (100 U/ml), streptomycin (100 |xg/ml), and gentami-
cin (5 p,g/ml). Synoviocytes were then infected in seram-free 
medium at moi from 10^ to 10* viral particles per target cell 
with Ad.RSV7L-7ra, and 10* viral particles per cell for Ad.RS-
V/acZ (control) for 4 hr, washed extensively, maintained in 
culture, and harvested 2 days post-infection. Total cellular 
D N A was isolated from the cells using standard methods. Ten 
micrograms oftotal cellular D N A and 1 pg and 10 pg of purified 
plasmid D N A from pAd.RSV7L-7ra were digested with B a m 
HI (human IL-lra c D N A contains a single B a m HI site) and 
analyzed by Southem blot using ̂ ^P-labeled probes specific for 
human IL-lra c D N A . Note the dose-dependent increase in copy 
number observed in the infected synoviocytes with respect to 
both adenoviral genomic D N A (upper arrow) and human IL-lra 
c D N A (lower arrow). The middle arrow indicates the location 
of the human IL-lra gene (11 kb) and is consistent in intensity 
across all lanes. Quantitative analysis of the blots using a M o -
lecular Dynamics phosphoimager was used to estimate the av-
erage number of adenoviral genomes/synoviocyte. Lane 1, 
Ad.RSV/acZ-infected cells (moi = 10'); lane 2, Ad.RSV/L-
/ra-infected cells (moi = 10^, O.S copies/cell); lane 3, Ad.RS-
V7L-7ra-infected cells (moi = 10', 1.0 copies/cell); lane 4, 
Ad.RSV7Z.-7ra-infected cells (moi = 10*, 6.0 copies/cell); 
lanes 5 and 6, 1 pg and 10 pg of pAd.RSV7L-7ra. 













FIG. 2. PGE2 production by cultured human synoviocytes in 
vitro after IL-1|3 stimulation. Multiple cultures of human rheu-
matoid synoviocytes from the same subject (n = 10) were in-
fected with recombinant adenoviras (Ad.RSV/acZ or Ad.RS-
NIL-lra at a moi of 10* pfu/cell). Mock-infected cells were 
carried in parallel. Three days later, cells were stimulated with 
rhIL-ip (3 U/ml) for a period of 12 hr in seram-free media. The 
total production of soluble P G E 2 by the experimental and con-
trol synoviocytes was determined by ELISA (PerSeptive Diag-
nostics) of tissue culture supematants, and the data expressed as 
picograms P G E 2 per milliliter. Uninfected cells produced sig-
nificant amounts of soluble PGE2 in response to IL-1 stimula-
tion (p < 0.001). Note that synoviocytes infected with Ad.RS-
NIL-lra produced significantiy less P G E j over the 12 hr of 
stimulation with IL-ip than cells infected with Ad.RSV/acZ 
(p < 0.001) or uninfected controls (p < 0.001). N o significant 
difference was observed in the levels of P G E j produced by 
mock-infected cells compared to Ad.RSV/acZ-infected cells 
(p = 0.067) after stimulation with IL-1. 
centrifugation, and the concentration of human IL-lra present 
in pooled lavage fluid determined using ELISA. The results of 
these experiments are shown in Table 2. Evidence for trans-
genic expression of IL-lra was detected within the knees of 
rabbits infected with Ad.RSNIL-lra at a dose of 2 x 10'" pfu/ 
knee for at least 4 weeks post-infection. Peak intra-articular 
concentrations of IL-lra were noted 1 week post infection (13.9 
ng/mg total protein) followed by a decline to levels less than 1 
log above the levels of IL-lra present in joint lavage fluid 
obtained from controls 14 days post-infection. Although the 
levels of IL-lra present in infected knees were greater than the 
levels in control knees at 21 and 28 days post-infection, these 
differences did not reach statistical significance when analyzed 
by Student's f-test. Levels of IL-lra present in the control knees 
infected with Ad.Bglll or Ad.RSV/acZ remained below SO 
pg/mg of total protein throughout the observation period. The 
data obtained in this series of experiments correlate with those 
obtained using the in situ c R N A hybridization studies, indicat-
ing that temporal declines in the rate of transgene transcription 
occur in vivo with these first-generation adenoviral vectors. 
These results are consistent with the observations of other in-
vestigators using first generation recombinant adenovirases for 
transduction of other tissues (Rich ef al., 1990; Rosenfeld ef 
al., 1992; Engelhardt ef a/., 1993). 
A second group of rabbits (n = 8) was injected with a single 
dose of Ad.RSWIL-Ira at a concentration of I x 1 0 " pfu/ml. 
At 4 and 7 days post-infection, all animals expressed high levels 
of intra-articular IL-lra, while the levels of IL-lra expression 
within the control knees (injected with 1 ml of PBS) remained at 
baseline levels (Fig. 4). All of the animals expressed IL-lra at 
potentially therapeutic levels at both 4 days (mean intra-articu-
lar [IL-lra] = 8.98 ng/mg total protein) and 7 days (mean intra-
articular [IL-lra] = 3.88 ng/mg total protein) post-infection. 
Again, levels of transgenic protein expression had begun to 
decline by 7 days in all animals examined. 
Although high levels of immunoreactive IL-lra were de-
tected in lavage fluid, an in vivo bioactivity assay was per-
formed to test the anti-inflammatory capacity of the transgenic 
protein. Intra-articular administration of rhIL-la in rabbits has 
been shown to induce an acute inflammatory process that re-
sults in the degradation of cartilage matrix and the accumulation 
of G A G degradation products within the treated knees (Fam-
daleefa/., 1982). Exogenous recombinant human IL-la (rhlL-
la, 25 ng/knee) was injected into the knees of three rabbits 4 
days post-infection with Ad.RSV7L-7ra and 24 hr prior to sac-
rifice. As seen in Fig. 5, prior Ad.RSV7L-7ra injection resulted 
in a reduction in the amount of G A G degradation products by 
nearly half as compared with contralateral control knees 
(Ad.RSV7L-7ra-treated mean [GAG] = 42.9 p-g/ml; PBS-
treated mean [GAG] = 88.1 p-g/ml; p « 0.03). These data in-
dicate that the secreted transgenic human IL-lra protein is not 
only immunoreactive, but retains bioactivity in vivo as mea-
sured by its ability to block articular inflammation mediated by 
exogenously administered recombinant human IL-la. 
DISCUSSION 
Current treatments for rheumatoid arthritis are associated 
with significant untoward effects and are largely ineffective in 
preventing end-organ damage, the destraction of articular carti-
lage and bone (Harris, 1990). Increasing evidence points to the 
pathophysiologic role of synoviocytes in erosive R A (Harris, 
1992; Gay ef al., 1993; Zvaifler and Firestein, 1994). Rheuma-
toid synoviocytes, which persist in a semitransformed pheno-
type, are thought to mediate articular degradation by secreting 
matrix metalloproteases (e.g., coUagenases, elastase, and 
stromelysin) and by elaborating proinflammatory cytokines 
(Brinkerhoff and H a m s , 1978; Burmester ef al., 1987; Case ef 
al., 1989;Alvaro-Graciaefa/., 1990; Chu ef a/., 1991;Kochef 
al., 1992;Rosenbaumefa/., 1992). 
Repeated intra-articular corticosteroid injections are the cur-
rent mainstay in managing the most problematic joints in ag-
gressive R A (Weiss, 1989; Firestein etal., 1991). Gene trans-
fer strategies that mediate the intra-articular expression of anti-
inflammatory molecules would be expected to have similar 
therapeutic utility if applied in such cases. This approach would 
allow treatments to be directed specifically at the most severely 
affected joints, with the goal being the amelioration of joint 
destmction and the preservation of joint function. 
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F I G . 3. In situ R N A hybridization of Ad.RSV7L-/ra-transduced synovial tissues. Sections of synovial tissue w e r e obtained from 
N Z W rabbits 1 w e e k after infection with A d . R S V I L - I r a . and used for in situ R N A hybridization experiments to detect transgene 
transcription. ''S-Labeled sense and antisense R N A probes specific for h u m a n IL-lra w e r e prepared by in vitro transcription using 
T7 polymerase and ['^S]UTP. Hybridizations were performed in 5 0 % fonnamide at 58°C using previously described methods 
(Roessler ef al., 1993). Slides were coated with photographic emulsion (Kodak NTB-2) and exposed for 4 days, developed, 
counterstained, and examined using a combination of light-field (left panels) and dark-field (right panels) microscopy to identify 
cells containing areas of specific antisense probe hybridization. Sections from Ad.RSV7L-7ra (B) or Ad.RSV/acZ (C) -infected 
animals were hybridized to radiolabeled antisense sequences, with only Ad.RSV7L-7/-a-infected tissues showing multiple positive 
cells. Synovial tissue from rabbits infected with Ad.RSV7L-7ra hybridized to sense probe exhibited background levels of signal 
(A). 
Because lL-1 appears to be a pivotal cytokine in R A , the 
intra-articular overexpression of IL-lra, its natural antagonist, 
would be expected to ameliorate the severity of IL-1-induced 
synovial inflammation. The previously reported expression of 
both IL-I and type 1 lL-1 receptors by human rheumatoid syn-
oviocytes lends additional support to this hypothesis (Deleuran 
ef al., 1992). In this report, w e have shown that the direct 
intra-articular administration of a recombinant adenoviras can 
be used to mediate the transgenic expression of biologically 
active IL-lra in both human and rabbit synoviocytes. The re-
combinant adenoviras was designed to prevent expression of 
viral genes that might in and of themselves have immunomodu-
latory effects. Therefore, w e believe that our data do not indi-
cate that any of these genes are responsible for the observed 
effects on P G E 2 production in vitro or on G A G degradation 
products in vivo. W e believe that the biological effects demon-
strated both in vitro and (/; vivo are modulated specifically by 
the transgenic human IL-la produced by transduced synovio-
cytes. 
These results are similar to those recently reported using an 
ex vivo system of retroviral gene transfer to autologous synovio-
cytes followed by intra-articular transplantation for the regional 
expression of transgenic IL-lra (Bandara ef al., 1993). The 
intra-articular levels of IL-lra recovered at 1 week were notably 
higher using direct in vivo gene transfer with recombinant ade-
novirases compared to intra-articular transplantation of retrovi-
rally transduced cells (—5.0 ng v.y. 0.1 ng of IL-lra/knee). 
Besides this improved transgene expression, a number of other 
potential advantages of intra-articular adenoviral injection over 
an ex vivo transduction strategy are apparent. The current ap-
proach does not require the surgical acquisition, isolation, and 
culture of autologous synoviocytes. Further, the recombinant 
GENE TRANSFER TO HUMAN SYNOVIUM 313 
Table 2. In Vivo Expression of Human IL-1ra Protein 








13.9. ± 1.8 
0.0936 ± 0.0241 
0.0768 ± 0.0347 
0.0543 ± 0.0311 
[IL-lra]^ 
Left knee'̂  
0.0494 ±0.0115 
0.0224 ± 0.0112 
0.0071 ± 0.0071 






N Z W rabbits (« = 4) received a single intra-articular dose of Ad. 
RSWIL-lra (2 X 10'° pfu/ml; total volume 1 ml) into the right knee, 
and at the same time the left knee was injected with 1 ml of PBS. The 
animals were then sacrificed at weekly intervals and analyzed for trans-
gene expression present within infected synovium. At the time of sacri-
fice, the knees were lavaged with 2 ml of PBS, cellular debris was 
removed by centrifugation, and the recovered fluid was frozen at 
-70°C until use. The concentration ofhuman IL-lra in the lavage fluid 
was determined using an ELISA specific for IL-lra, and the total 
protein concentration was determined using the method of Lowry. The 
values were recorded as ng of IL-lra/mg of total protein present in the 
lavage fluids. 
'IL-lra (ng/mg total protein). 
''Ad.RSV/L-7ra. 
'PBS control. 
adenoviral strategy allows for the transduction of both type A 
and type B synoviocytes (Roessler ef al., 1993), as well as other 
cell types residing in the subsynovial connective tissue. This 
may prove to be therapeutically important. Although the syn-
ovium is often constraed as a simple constract, it is actually a 
complex mesothelium with highly integrated stracture and 
function, and transduction of multiple cell types may be re-
quired for a clinical effect. 
The major limitation to the approach we have presented is 
that in vivo, peak levels of expression were detected at 4-7 days 
post-infection and then progressively declined. These results 
are identical to those observed in other organ systems trans-
duced with recombinant adenovirases. Although IL-lra trans-
gene expression was detectable for up to 1 month using adeno-
viral transduction, the use of an ex vivo system has been 
reported to result in detectable levels of IL-lra expression for up 
to 3 months (Bandara ef al., 1993). N e w recombinant adenovi-
rases with temperature-sensitive mutations in early gene 2A 
have been developed that result in prolonged expression (sev-
eral months vs. 21 days) in liver and lung (Engelhardt ef al., 
1994a,b). The production of second-generation adenovirases 
for the prolonged in vivo expression of human IL-lra are cur-
rently underway. 
In summary, this report has shown that recombinant adenovi-
ral vectors can mediate expression ofhuman IL-lra by synovial 
tissues in vitro and in vivo, and demonstrates that adenovirally 
transduced synoviocytes can mediate expression of a secreted 
anti-inflammatory protein. Importantly, the transgenic protein 
retains biological activity in vitro and in vivo as measured by its 
ability to block the proinflammatory effects of exogenously 





Days post- infection 
FIG. 4. Detection of transgenic human IL-
lra bioactivity in vivo. N Z W rabbits (n = 8) 
were injected with a single intra-articular dose 
of Ad.RSV7L-7ra to determine if the levels of 
transgenic IL-lra produced in vivo varied sig-
nificantly between animals. The right knee of 
the recipient animals received Ad.RSV/Z,-7ra 
(1 X 10" pfu/ml, total volume 1 ml), while 
the left knee was injected with 1 ml of vehicle 
alone (PBS containing 3 % glycerol and 0.1% 
BSA ) . The animals were sacrificed at 4 days 
and 7 days post-infection, the joint spaces 
Ad.KS\IL-Ira were lavaged with 2 ml of PBS, cellular debris 
was removed by centrifugation, and the recov-
Control ered fluid was frozen at -70°C until use. The 
concentration of human IL-lra present in the 
lavage fluid was determined using an ELISA 
specific for IL-lra and expressed as nanograms 
of IL-lra/mg total protein present in the recov-
ered lavage fluid (Fig. 4). Therapeutically rel-
evant amounts of human IL-lra were present 
within the joint space of animals treated with 
Ad.RSV7L-7ra (•) at both 4 and 7 days post-
infection, while the levels of endogenous IL-
lra present within the contralateral control 
knee ( 0 ) remained below 0.150 ng/mg total 
protein (p < = 0.008). Levels of transgenic 
human IL-lra produced by the rabbits were 
highest at 4 days post-infection and had begun 
to decline by 7 days post-infection. Error bars 
indicate the standard deviation observed 
£unong 4 animals at each time point. 
















C3 Ad.RSV/L-7ra OL-lra) 
H Control (IL-lra) 
fU Ad.RSV/Z.-/ra(GAG) 
E3 Control (GAG) 
1 2 3 
Rabbit 
FIG. 5. Bioactive IL-lra is expressed following Ad.RSNIL-lra transduction of synovial tissue. The hind knees of rabbits 
(n = 3) were injected with 25 ng of human recombinant IL-la (Genzyme) in 0.5 ml of PBS containing 3 % glycerol and 0.1% 
BSA, either 3 days (rabbit 1) or 6 days (rabbits 2 and 3) after treatment with Ad.RSV77.-7ra. Twenty-four hours after the injections 
ofhuman recombinant IL-la, the animals were sacrificed and the joint spaces were lavaged with 2 ml of PBS. The lavage fluids 
were then analyzed for human IL-lra as well as total G A G concentration (Famdale et al., 1982). The results were expressed as 
nanograms of IL-lra/mg total protein, and micrograms of G A G / m L present within the recovered lavage fluid. The amount of 
lL-1-mediated G A G matrix (cartilage) degradation observed in the Ad.RSV7L-7ra-treated knees was less than that observed in the 
contralateral control knees (Ad.RSV77.-7ra-treated mean [GAG] = 42.9 |xg/ml; PBS-treated mean [GAG] = 88.1 p-g/ml; 
p < =0.03). 
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